Article
Following on the heels of the FDA's advice on the risk of using morcellators for treating fibroids, researchers in France have released results of a study that delineates a method that can avoid the risk of morcellating a pre-existing uterine sarcoma.
A thorough preop work-up can just about eliminate the risk of accidentally morcellating an occult uterine sarcoma, according to a prospective series of 2824 women referred for minimally invasive myomectomy to a French university hospital from 2002 to 2013.
The message came just days before the Food and Drug Administration’s Nov. 24 advice not to use “power morcellation during hysterectomy or myomectomy for uterine fibroids” because “there is no reliable method for predicting whether a woman with fibroids may have a uterine sarcoma” that morcellation could spread. The agency estimated that about 1 in 350 fibroid patients actually have an occult sarcoma.
Read the complete report: http://bit.ly/1y1zDwm
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
Incorporating Discussions of Cannabis Use Into Oncology Care Visits